EEM Rewind: The PECARN Fever Rule

Well-appearing febrile infants 29 to 60 days old can be risk-stratified for serious bacterial infection with three objective tests: urinalysis, absolute neutrophil count, and procalcitonin. PECARN outperforms older fever rules on specificity while maintaining very high sensitivity, but age, exclusions, and biomarker availability matter.

PECARN Fever Rule Basics

• Age window and appearance: PECARN applies only to clinically well infants 29 to 60 days old; the first 3 weeks are a different HSV-heavy risk zone, with age nuances we get into in the episode.
• Key exclusion criteria: Former prematurity, antibiotics in the prior 48 hours, congenital malformation, chronic illness, and indwelling devices push patients outside the rule before you ever interpret labs.
• Three objective variables: The rule uses a negative urinalysis, ANC, and procalcitonin rather than subjective clinical impressions, which makes it easier to standardize and embed in the EHR.
• Performance characteristics: PECARN showed about 98% sensitivity with roughly 60% specificity, meaning many low-risk infants can avoid lumbar puncture, antibiotics, and admission.
• Procalcitonin requirement: Procalcitonin is not optional in PECARN; if your institution cannot obtain it, you cannot claim the rule has been applied as validated.

Clinical Caveats and Practical Use

• Serious infection prevalence: In the derivation and validation cohort, about 9% had a serious bacterial infection, mostly UTI, with bacteremia and meningitis far less common but still consequential.
• Positive urinalysis nuance: A positive UA does not carry the same implication across both months of life; in older infants, blood testing and E coli coverage become central, and we walk through that distinction in the chapter.
• Fever duration debate: A rigid fever-duration cutoff is less reliable than it sounds, especially when onset depends on parent report, and external validation concerns matter when interpreting short-duration fever data.
• Lumbar puncture limits: PECARN helps identify infants at low risk for invasive bacterial infection, but it does not erase meningitis or HSV from the differential, especially in the youngest babies.
• Older rules comparison: Compared with Boston, Rochester, and Philadelphia criteria, PECARN and Step-by-Step rely on modern biomarkers and better statistical derivation rather than expert consensus alone.

References:

1.) Kuppermann N, et al; Febrile Infant Working Group of the Pediatric Emergency Care Applied Research Network (PECARN). A Clinical Prediction Rule to Identify Febrile Infants 60 Days and Younger at Low Risk for Serious Bacterial Infections. JAMA Pediatr. 2019 Apr 1;173(4):342-351. PMID: 30776077.

2.) Aronson PL, et al; Febrile Young Infant Research Collaborative. A Prediction Model to Identify Febrile Infants ≤60 Days at Low Risk of Invasive Bacterial Infection. Pediatrics. 2019 Jul;144(1):e20183604. PMID: 31167938.

3.) Velasco R, et al. Accuracy of PECARN rule for predicting serious bacterial infection in infants with fever without a source. Arch Dis Child. 2021 Feb;106(2):143-148. PMID: 32816694.

4.) Burstein B, et al. Prevalence of Bacterial Meningitis Among Febrile Infants Aged 29-60 Days With Positive Urinalysis Results: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021 May 3;4(5):e214544. PMID: 33978724.